Loading…
Underlying
Underlying Price
$6.01
Type
Call
Strike
6
Expiration
Dec 4, 2026
DTE
21d
Moneyness
ITM
Intrinsic
$0.01
IBRX 6 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0d | $2.60 | +0.00% | 4 | 121 |
| Nov 20, 2026 | 7d | $2.44 | -30.29% | 2 | 330 |
| Nov 27, 2026 | 14d | $2.74 | -30.10% | 2 | 1 |
| Dec 4, 2026 | 21d | — | — | 0 | 523 |
| Dec 11, 2026 | 28d | — | — | 0 | 50 |
| Dec 18, 2026 | 35d | $2.67 | +0.00% | 1 | 12 |
| Dec 24, 2026 | 41d | — | — | 0 | 15 |
| Dec 31, 2026 | 48d | — | — | 0 | 0 |
| Mar 19, 2027 | 126d | $3.50 | -21.35% | 1 | 289 |
| Apr 16, 2027 | 154d | $3.42 | -12.31% | 3 | 59 |
| May 21, 2027 | 189d | $3.30 | +0.00% | 1 | 15 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.